BPC-157 vs LL-37: Tissue Repair vs Antimicrobial Peptide Comparison | Peptpedia
This comprehensive analysis compares BPC-157 and LL-37 based on peer-reviewed clinical research, examining their mechanisms of action, efficacy data, and safety profiles. For complete individual peptide profiles, visit the dedicated research pages linked above.
BPC-157 and LL-37 are both studied for wound healing but through distinct mechanisms: BPC-157 promotes tissue repair through angiogenesis, fibroblast activation, and nitric oxide modulation; LL-37 provides antimicrobial defense while simultaneously signaling keratinocyte migration and immune cell activation. They are complementary rather than competing, with BPC-157 addressing structural repair and LL-37 addressing infection defense and innate immune signaling during wound healing.
Chemical Identity
Side-by-Side Comparison
| Property | BPC-157 | LL-37 |
|---|---|---|
| Origin | Synthetic (derived from gastric juice protein) | Endogenous (human cathelicidin, hCAP18 cleavage) |
| Primary Action | Tissue repair: angiogenesis, fibroblast activation | Antimicrobial + immune signaling |
| Length | 15 amino acids | 37 amino acids |
| Wound Healing Role | Structural repair (tendon, muscle, gut, skin) | Infection defense + keratinocyte migration |
| Research Status | Extensive preclinical; no human RCTs | Phase 1-2 clinical trials (wound care) |
| Anti-inflammatory | Yes (via NO and FAK pathways) | Context-dependent (pro- or anti-inflammatory) |
Mechanism of Action: Structural Repair vs Immune Defense
BPC-157 promotes tissue repair through multiple mechanisms: upregulation of growth hormone receptors in fibroblasts (amplifying their response to healing signals), activation of the FAK-paxillin pathway (promoting cell adhesion and migration), modulation of the nitric oxide system (enhancing vascular function and blood flow), and dual activation of the Egr-1/NAB2 gene loop (driving organized angiogenesis). These mechanisms are particularly relevant to tendon, muscle, gut mucosal, and skin repair in animal models.
LL-37 functions as both a direct antimicrobial and an immune signaling peptide. As a cationic amphipathic helix, it disrupts bacterial cell membranes through electrostatic interaction. Beyond killing, it activates formyl peptide receptor 2 (FPR2) on immune cells, recruits and activates neutrophils and macrophages, stimulates keratinocyte migration for wound re-epithelialization, and promotes angiogenesis through VEGF upregulation. Its role in wound healing bridges innate immunity and tissue repair.
Frequently Asked Questions
Research Citations
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. (2011). Current Pharmaceutical Design